Latest news
StockWatch: Lilly Rises on Revenue Leap; Analysts High on Krystal Despite Revenue Miss - Genetic Engineering and Biotechnology NewsGenetic Engineering and Biotechnology News · Mon, 10 Aug 2026 04:37:02 GMTEli Lilly: 'Strong Buy' On Retatrutide Obesity Drug And EBGLYSS Maintenance Label Expansion - Seeking AlphaSeeking Alpha · Fri, 07 Aug 2026 22:29:17 GMTResmed says weight-loss pills are driving sleep device demand - AFRAFR · Fri, 07 Aug 2026 02:46:00 GMTEli Lilly Surpasses Wall Street Estimates on Injectable GLP-1 Drugs - Pharmaceutical ExecutivePharmaceutical Executive · Thu, 06 Aug 2026 14:12:46 GMTEli Lilly’s Obesity Drugs Drive Massive Revenue Growth - ForbesForbes · Wed, 05 Aug 2026 21:00:36 GMTLilly's GLP-1 Drugs Just Blew Sales Expectations Out Of The Water - Investor's Business DailyInvestor's Business Daily · Wed, 05 Aug 2026 20:07:00 GMTLilly beats estimates on resilient demand for injectable GLP-1 drugs, widens gap with Novo - reuters.comreuters.com · Wed, 05 Aug 2026 17:51:09 GMTWatch Eli Lilly posts 48% revenue growth driven by blockbuster obesity drugs - The Big Money Show - FOX OneFOX One · Wed, 05 Aug 2026 17:27:50 GMT